Roche has its Cake--and Eats it
Executive Summary
Roche has always been a strategic trailblazer--both in acquiring a biotech and now spinning it off. Genentech's employees are delighted and Roche, with its IPO of Genentech shares, may have hit on a way of both financing its buyback of Genentech's stock and keeping its key scientists motivated.